arrow
G

Giuseppe Viale

University of Milano
H指数:157
被引数:11.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to: “Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis” [Eur J Cancer 145 (2021) 197–209]

勘误: “Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis” [Eur J Cancer 145 (2021) 197–209]

2025-11-290
PRE
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

远处无病生存期作为早期乳腺癌新辅助治疗随机试验中总生存期的替代终点:GBG和AGO-B研究组试验的合并分析

2025-11-240
PRE
A Global Ring Study: Concordance Between Ventana PATHWAY anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-low Breast Cancer

全球环研究:Ventana PATHWAY anti-HER2/neu (4B5) 伴随诊断检测试剂盒与比较检测HER2低表达乳腺癌的一致性研究

2025-08-090
OAAI
Sex hormones, the anticancer immune response, and therapeutic opportunities

性激素,抗癌免疫反应和治疗机会

2025-03-011
OAAI
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (sept,10.1038/s41591-024-03261-7,2024)
2024-12-090
OAAI
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

曲妥珠单抗deruxtecan HER2-positive晚期乳腺癌伴或不伴脑转移: 3b/4期试验

2024-09-137
OAAI
Tailoring neo/adjuvant systemic therapy in breast cancer: The advent of a personalized approach-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations

定制乳腺癌的新/辅助系统治疗: 个性化方法的出现-乳腺妇科和免疫肿瘤学国际癌症会议 (BGICC) 共识和建议

CANCER
IF5.1
2024-07-100
PRE
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

停用免疫检查点抑制剂的晚期实体瘤患者的结局: 系统回顾和荟萃分析

2024-07-010
OAAI
Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
2024-05-024
PRE
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
2024-05-020
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
Different molecular processes are associated with recurrence in the clinical high-genomic low risk (cH/gL) and clinical low- genomic high risk (cL/gH) groups of the MINDACT clinical trial
2024-05-020
PRE
Exemestane and breast cancer prevention: how low can we go? Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative dosing regimen
2024-05-020
PRE
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ

乳腺导管原位癌患者免疫相关基因表达与乳腺癌复发的关系

2024-05-010
OA
HER2 heterogeneity and treatment response- associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

NCT02326974临床试验中HER2-positive乳腺癌的HER2异质性和治疗反应相关特征

2024-02-012
OAAI
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation
2024-01-181
OA